The Level of Laboratory Testing Required for Diagnosis or Exclusion of a Platelet Function Disorder Using Platelet Aggregation and Secretion Assays

ABSTRACT

The major advances from research on platelet molecular and cell biology, physiology, and pathophysiology over the past decades have not been adequately translated to clinical laboratory diagnosis. Hereditary platelet function disorders (PFDs) are at least as prevalent in the general population as von Willebrand disease (VWD) although PFDs tend not be as well recognized or evaluated. Clinical mucous and skin bleeding in patients with PFDs is prototypic of primary hemostasis disorders, and the bleeding pattern is not distinguishable from that of other primary hemostasis disorders such as VWD. However, different treatment needs, between these discrete disorders, make a precise diagnosis mandatory. Currently, clinicians receive reliable laboratory reports when testing patients with severe PFDs, such as Glanzmann thrombasthenia and Bernard-Soulier syndrome, due to the distinctive laboratory defects that these disorders present, together with the availability of differential diagnostic tests. This is not the case for the majority of PFDs generically classified as “platelet secretion disorders,” which are a heterogeneous group of “mild bleeding disorders,” for which there are not universally accepted diagnostic criteria. An important reason for robust diagnostic tests is the high proportion (more than 50% in some reports) of patients with unequivocal bleeding who have no precise diagnosis established after a complete laboratory workup. It is paradoxical that the current “gold standard” test for PFD diagnosis, light transmission aggregometry (LTA), has not been standardized after more than four decades of worldwide clinical use. This review describes current diagnostic assays for PFD in a clinical hemostasis laboratory, relating these with current knowledge on platelet function and pathophysiology. Special emphasis will be given to LTA and platelet secretion tests, as well as to the reasons why sensitive tests are needed to explore the lesser known participation of platelets in blood clotting and fibrinolytic processes.

KEYWORDS

Platelet aggregation tests - platelet secretion tests - platelet secretion defects

REFERENCES

• 1 Quiroga T, Goycoolea M, Panes O et al.. High prevalence of bleeders of unknown cause among patients with inherited mucocutaneous bleeding. A prospective study of 280 patients and 299 controls.  Haematologica. 2007;  92 357-365
• 2 Favaloro E J. Investigating people with mucocutaneous bleeding suggestive of primary hemostatic defects: a low likelihood of a definitive diagnosis?.  Haematologica. 2007;  92 292-296
• 3 Pereira J, Quiroga T, Mezzano D. Laboratory assessment of familial, nonthrombocytopenic mucocutaneous bleeding: a definitive diagnosis is often not possible.  Semin Thromb Hemost. 2008;  34 654-662
• 4 Cattaneo M. Inherited platelet-based bleeding disorders.  J Thromb Haemost. 2003;  1 1628-1636
• 5 Rao A K, Jalagadugula G, Sun L. Inherited defects in platelet signaling mechanisms.  Semin Thromb Hemost. 2004;  30 525-535
• 6 George J N, Colman R W. Overview of platelet structure and function. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th ed. Philadelphia, PA; Lippincott Williams & Wilkins 2006: 437-441
• 7 Clemetson K J, Clemetson J M. Platelet collagen receptors.  Thromb Haemost. 2001;  86 189-197
• 8 Parise L V, Smyth S, Shet A S, Coller B S. Platelet morphology, biochemistry and function. In: Lichtman EB, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT Williams Hematology. 6th ed. New York, NY; McGraw-Hill 2006: 1-60
• 9 Solum N O. Procoagulant expression in platelets and defects leading to clinical disorders.  Arterioscler Thromb Vasc Biol. 1999;  19 2841-2846
• 10 Walsh P N. Platelet coagulation-protein interactions.  Semin Thromb Hemost. 2004;  30 461-471
• 11 Monroe D M, Hoffman M. Coagulation factor interaction with platelets.  Thromb Haemost. 2002;  88 179
• 12 Janeway C M, Rivard G E, Tracy P B, Mann K G, Factor V. Factor V Quebec revisited.  Blood. 1996;  87 3571-3578
• 13 Oliver J A, Monroe D M, Church F C, Roberts H R, Hoffman M. Activated protein C cleaves factor Va more efficiently on endothelium than on platelet surfaces.  Blood. 2002;  100 539-546
• 14 Dale G L. Coated-platelets: an emerging component of the procoagulant response.  J Thromb Haemost. 2005;  3 2185-2192
• 15 Goel M S, Diamond S L. Factor VIIa-mediated tenase function on activated platelets under flow.  J Thromb Haemost. 2004;  2 1402-1410
• 16 Camera M, Frigerio M, Toschi V et al.. Platelet activation induces cell-surface immunoreactive tissue factor expression, which is modulated differently by antiplatelet drugs.  Arterioscler Thromb Vasc Biol. 2003;  23 1690-1696
• 17 Panes O, Matus V, Sáez C G, Quiroga T, Pereira J, Mezzano D. Human platelets synthesize and express functional tissue factor.  Blood. 2007;  109 5242-5250
• 18 Monroe D M, Hoffman M, Roberts H R. Platelets and thrombin generation.  Arterioscler Thromb Vasc Biol. 2002;  22 1381-1389
• 19 Rauch U, Bonderman D, Bohrmann B et al.. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor.  Blood. 2000;  96 170-175
• 20 Siddiqui F A, Desai H, Amirkhosravi A, Amaya M, Francis J L. The presence and release of tissue factor from human platelets.  Platelets. 2002;  13 247-253
• 21 Schwertz H, Tolley N D, Foulks J M et al.. Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombogenicity of human platelets.  J Exp Med. 2006;  203 2433-2440
• 22 Mezzano D, Matus V, Sáez C G, Pereira J, Panes O. Tissue factor storage, synthesis and function in normal and activated human platelets.  Thromb Res. 2008;  122(Suppl 1) S31-S36
• 23 Panes O, Ibarra P, Matus V, Sáez C G, Pereira J, Mezzano D. Platelet tissue factor: expression of pro-coagulant activity depends on GPIbα activation and signaling through Lyn-mediated phosphorylation. A platelet-based model of hemostasis.  Blood. 2008;  112 48(A113)
• 24 Weiss H. Impaired platelet procoagulant mechanisms in patients with bleeding disorders.  Semin Thromb Hemost. 2009;  35 233-241
• 25 Brogren H, Karlsson L, Andersson M, Wang L, Erlinge D, Jern S. Platelets synthesize large amounts of active plasminogen activator inhibitor 1.  Blood. 2004;  104 3943-3948
• 26 Braaten J V, Handt S, Jerome W G, Kirkpatrick J, Lewis J C, Hantgan R R. Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor 1: light scattering and ultrastructural examination of lysis of a model platelet-fibrin thrombus.  Blood. 1993;  81 1290-1299
• 27 Plow E F, Collen D. The presence and release of alpha 2-antiplasmin from human platelets.  Blood. 1981;  58 1069-1074
• 28 Reed G L, Matsueda G R, Haber E. Platelet factor XIII increases the fibrinolytic resistance of platelet-rich clots by accelerating the crosslinking of alpha 2-antiplasmin to fibrin.  Thromb Haemost. 1992;  68 315-320
• 29 Mosnier L O, Buijtenhuijs P, Marx P F, Meijers J C, Bouma B N. Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets.  Blood. 2003;  101 4844-4846
• 30 Sheth P M, Kahr W H, Haq M A, Veljkovic D K, Rivard G E, Hayward C P. Intracellular activation of the fibrinolytic cascade in the Quebec platelet disorder.  Thromb Haemost. 2003;  90 293-298
• 31 Gurewich V, Johnstone M, Loza J P, Pannell R. Pro-urokinase and prekallikrein are both associated with platelets. Implications for the intrinsic pathway of fibrinolysis and for therapeutic thrombolysis.  FEBS Lett. 1993;  318 317-321
• 32 Veljkovic D K, Rivard G E, Diamandis M et al.. Increased expression of urokinase plasminogen activator in Quebec platelet disorder is linked to megakaryocyte differentiation.  Blood. 2009;  113 1535-1542
• 33 Rao A K. Molecular and biochemical basis for the platelet dysfunction in myeloproliferative disorders.  Semin Hematol. 2004;  41(2, Suppl 3) 6-9
• 34 Coller B S, French D L. Hereditary qualitative platelet disorders. In: Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT Williams Hematology. 7th ed. New York, NY; McGraw-Hill 2006: 1551-1582
• 35 Cattaneo M. Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function.  Semin Thromb Hemost. 2009;  35 158-167
• 36 Gobbi G, Sponzilli I, Mirandola P et al.. Efficient platelet delta-granule release induced by [Ca2+]i elevation is modulated by GPIIbIIIa.  Int J Mol Med. 2006;  18 309-313
• 37 Nieuwenhuis H K, Akkerman J W, Sixma J J. Patients with a prolonged bleeding time and normal aggregation tests may have storage pool deficiency: studies on one hundred six patients.  Blood. 1987;  70 620-623
• 38 Israels S J, McNicol A, Robertson C, Gerrard J M. Platelet storage pool deficiency: diagnosis in patients with prolonged bleeding times and normal platelet aggregation.  Br J Haematol. 1990;  75 118-121
• 39 Miller J. Glycoprotein analysis for the diagnostic evaluation of platelet disorders.  Semin Thromb Hemost. 2009;  35 224-232
• 40 Arthur J F, Dunkley S, Andrews R K. Platelet glycoprotein VI-related clinical defects.  Br J Haematol. 2007;  139 363-372
• 41 Nieuwenhuis H K, Sakariassen K S, Houdijk W P, Nievelstein P F, Sixma J J. Deficiency of platelet membrane glycoprotein Ia associated with a decreased platelet adhesion to subendothelium: a defect in platelet spreading.  Blood. 1986;  68 692-695
• 42 Jung S M, Moroi M. Activation of the platelet collagen receptor integrin alpha(2)beta(1): its mechanism and participation in the physiological functions of platelets.  Trends Cardiovasc Med. 2000;  10 285-292
• 43 Miura Y, Takahashi T, Jung S M, Moroi M. Analysis of the interaction of platelet collagen receptor glycoprotein VI (GPVI) with collagen. A dimeric form of GPVI, but not the monomeric form, shows affinity to fibrous collagen.  J Biol Chem. 2002;  277 46197-46204
• 44 Nurden A T. Qualitative disorders of platelets and megakaryocytes.  J Thromb Haemost. 2005;  3 1773-1782
• 45 Salles I I, Feys H B, Iserbyt B F, De Meyer S F, Vanhoorelbeke K, Deckmyn H. Inherited traits affecting platelet function.  Blood Rev. 2008;  22 155-172
• 46 Hayward C P. Inherited platelet disorders.  Curr Opin Hematol. 2003;  10 362-368
• 47 Nurden P, Nurden A T. Congenital disorders associated with platelet dysfunctions.  Thromb Haemost. 2008;  99 253-263
• 48 Sims P J, Wiedmer T, Esmon C T, Weiss H J, Shattil S J. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity.  J Biol Chem. 1989;  264 17049-17057
• 49 Diamandis M, Veljkovic D K, Maurer-Spurej E, Rivard G E, Hayward C P. Quebec platelet disorder: features, pathogenesis and treatment.  Blood Coagul Fibrinolysis. 2008;  19 109-119
• 50 Gupta P K, Charan V D, Saxena R. Spectrum of von Willebrand disease and inherited platelet function disorders amongst Indian bleeders.  Ann Hematol. 2007;  86 403-407
• 51 Diamandis M, Adam F, Kahr W H et al.. Insights into abnormal hemostasis in the Quebec platelet disorder from analyses of clot lysis.  J Thromb Haemost. 2006;  4 1086-1094
• 52 Fay W P, Eitzman D T, Shapiro A D, Madison E L, Ginsburg D. Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1-dependent and -independent mechanisms.  Blood. 1994;  83 351-356
• 53 Fay W P, Shapiro A D, Shih J L, Schleef R R, Ginsburg D. Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation.  N Engl J Med. 1992;  327 1729-1733
• 54 Fay W P, Parker A C, Condrey L R, Shapiro A D. Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene.  Blood. 1997;  90 204-208
• 55 Takahashi Y, Tanaka T, Minowa H et al.. Hereditary partial deficiency of plasminogen activator inhibitor-1 associated with a lifelong bleeding tendency.  Int J Hematol. 1996;  64 61-68
• 56 Agren A, Wiman B, Stiller V et al.. Evaluation of low PAI-1 activity as a risk factor for hemorrhagic diathesis.  J Thromb Haemost. 2006;  4 201-208
• 57 Agren A, Wiman B, Schulman S. Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity.  Blood Coagul Fibrinolysis. 2007;  18 657-660
• 58 Agren A, Kolmert T, Wiman B, Schulman S. Low PAI-1 activity in relation to the risk for perioperative bleeding complications in transurethral resection of the prostate.  Thromb Res. 2007;  119 715-721
• 59 Tosetto A, Castaman G, Rodeghiero F. Assessing bleeding in von Willebrand disease with bleeding score.  Blood Rev. 2007;  21 89-97
• 60 Pai M, Hayward C. Diagnostic assessment of platelet disorders: what are the challenges to standardization?.  Semin Thromb Hemost. 2009;  35 131-138
• 61 Rodgers R P, Levin J. A critical reappraisal of the bleeding time.  Semin Thromb Hemost. 1990;  16 1-20
• 62 Lind S E. The bleeding time does not predict surgical bleeding.  Blood. 1991;  77 2547-2552
• 63 Peterson P, Hayes T E, Arkin C F et al.. The preoperative bleeding time test lacks clinical benefit: College of American Pathologists' and American Society of Clinical Pathologists' position article.  Arch Surg. 1998;  133 134-139
• 64 Triplett D A. The bleeding time. Neither pariah or panacea.  Arch Pathol Lab Med. 1989;  113 1207-1208
• 65 Favaloro E J. Clinical utility of the PFA-100.  Semin Thromb Hemost. 2008;  34 709-733
• 66 Harrison P, Mumford A. Screening tests of platelet function: update on their appropriate uses for diagnostic testing.  Semin Thromb Hemost. 2009;  35 150-157
• 67 Buyukasik Y, Karakus S, Goker H et al.. Rational use of the PFA-100 device for screening of platelet function disorders and von Willebrand disease.  Blood Coagul Fibrinolysis. 2002;  13 349-353
• 68 Harrison P, Robinson M, Liesner R et al.. The PFA-100: a potential rapid screening tool for the assessment of platelet dysfunction.  Clin Lab Haematol. 2002;  24 225-232
• 69 Favaloro E J, Bonar R, Duncan E, Rodgers S, Marsden K. Royal College of Pathologists of Australasia Quality Assurance Program in Haematology . Utility of the PFA-100 as a screening test of platelet function: an audit of haemostasis laboratories in Australia and New Zealand.  Blood Coagul Fibrinolysis. 2007;  18 441-448
• 70 Favaloro E J. Clinical application of the PFA-100.  Curr Opin Hematol. 2002;  9 407-415
• 71 Cattaneo M, Lecchi A, Agati B, Lombardi R, Zighetti M L. Evaluation of platelet function with the PFA-100 system in patients with congenital defects of platelet secretion.  Thromb Res. 1999;  96 213-217
• 72 Kerényi A, Schlammadinger A, Ajzner E et al.. Comparison of PFA-100 closure time and template bleeding time of patients with inherited disorders causing defective platelet function.  Thromb Res. 1999;  96 487-492
• 73 Quiroga T, Goycoolea M, Muñoz B et al.. Template bleeding time and PFA-100 have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: comparative study in 148 patients.  J Thromb Haemost. 2004;  2 892-898
• 74 Podda G M, Bucciarelli P, Lussana F, Lecchi A, Cattaneo M. Usefulness of PFA-100 testing in the diagnostic screening of patients with suspected abnormalities of hemostasis: comparison with the bleeding time.  J Thromb Haemost. 2007;  5 2393-2398
• 75 Hayward C P, Harrison P, Cattaneo M, Ortel T L, Rao A K. The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis . Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function.  J Thromb Haemost. 2006;  4 312-319
• 76 Baumgartner H R. The role of blood flow in platelet adhesion, fibrin deposition, and formation of mural thrombi.  Microvasc Res. 1973;  5 167-179
• 77 Sakariassen K S, Hanson S R, Cadroy Y. Methods and models to evaluate shear-dependent and surface reactivity-dependent antithrombotic efficacy.  Thromb Res. 2001;  104 149-174
• 78 Born G V. Aggregation of blood platelets by adenosine diphosphate and its reversal.  Nature. 1962;  194 927-929
• 79 O'Brien J R. Platelet aggregation: part II. Some results from a new method of study.  J Clin Pathol. 1962;  15 452-455
• 80 Michelson A D, Frelinger III A L, Furman M I. Current options in platelet function testing.  Am J Cardiol. 2006;  98 4N-10N
• 81 Pockham M, Kinlough , Rathbone R-L, Musta J F. Aggregation and agglutination. In: Day HJ, Holmsen H, Zucker MB Platelet Function Testing. NIH Publication No. 78–1087 Bethesda, MD; DHEW 1976: 66-92
• 82 The British Society for Haematology BCSH Haemostasis and Thrombosis Task Force . Guidelines on platelet function testing.  J Clin Pathol. 1988;  41 1322-1330
• 83 Christie D JAT, Carrington L R, Cohen E et al.. Platelet Function Testing by Aggregometry; Approved Guideline. Wayne, PA; Clinical Laboratory Standards Institute 2008: 1-43
• 84 Zhou L, Schmaier A H. Platelet aggregation testing in platelet-rich plasma: description of procedures with the aim to develop standards in the field.  Am J Clin Pathol. 2005;  123 172-183
• 85 Hayward C P, Eikelboom J. Platelet function testing: quality assurance.  Semin Thromb Hemost. 2007;  33 273-282
• 86 Favaloro E J. Internal quality control and external quality assurance of platelet function tests.  Semin Thromb Hemost. 2009;  35 139-149
• 87 Moffat K A, Ledford-Kraemer M R, Nichols W L, Hayward C P. North American Specialized Coagulation Laboratory Association . Variability in clinical laboratory practice in testing for disorders of platelet function: results of two surveys of the North American Specialized Coagulation Laboratory Association.  Thromb Haemost. 2005;  93 549-553
• 88 Jennings I WT, Woods T A, Kitchen S, Walker I D. Platelet function testing: practice among UK National External Quality Assessment Scheme for Blood Coagulation participants, 2006.  J Clin Pathol. 2008;  61 950-954
• 89 Duncan E M, Bonar R, Rodgers S E, Favaloro E J, Marsden K. RCPA QAP in Haematology, Haemostasis Committee . Methodology and outcomes of platelet aggregation testing in Australia, New Zealand and the Asia-Pacific region: results of a survey from the Royal College of Pathologists of Australasia Haematology Quality Assurance Program.  Int J Lab Hematol. 2008;  , March 21 doi: 10-1111/j1751-553×.2008.01051.×
• 90 Hevelow M E, McKenzie S M, Siegel J E. Reproducibility of platelet function testing.  Lab Hematol. 2007;  13 59-62
• 91 Ghosh K, Nair S, Kulkarni B, Khare A, Shetty S, Mohanty D. Platelet function tests using platelet aggregometry: need for repetition of the test for diagnosis of defective platelet function.  Platelets. 2003;  14 351-354
• 92 Hayward C P, Pai M, Liu Y et al.. Diagnostic utility of light transmission platelet aggregometry: results from a prospective study of individuals referred for bleeding disorder assessments.  J Thromb Haemost. 2009;  7 676-684
• 93 Kambayashi J, Shinoki N, Nakamura T et al.. Prevalence of impaired responsiveness to epinephrine in platelets among Japanese.  Thromb Res. 1996;  81 85-90
• 94 Hayward C P, Moffat K A, Pai M et al.. An evaluation of methods for determining reference intervals for light transmission platelet aggregation tests on samples with normal or reduced platelet counts.  Thromb Haemost. 2008;  100 134-145
• 95 Gaxiola B, Friedl W, Propping P. Epinephrine-induced platelet aggregation. A twin study.  Clin Genet. 1984;  26 543-548
• 96 Rao A K, Willis J, Kowalska M A, Wachtfogel Y T, Colman R W. Differential requirements for platelet aggregation and inhibition of adenylate cyclase by epinephrine. Studies of a familial platelet alpha 2-adrenergic receptor defect.  Blood. 1988;  71 494-501
• 97 Alexander R W, Cooper B, Handin R I. Characterization of the human platelet alpha-adrenergic receptor. Correlation of [3H]dihydroergocryptine binding with aggregation and adenylate cyclase inhibition.  J Clin Invest. 1978;  61 1136-1144
• 98 O'Brien J R. Variability in the aggregation of human platelets by adrenaline.  Nature. 1964;  202 1188-1190
• 99 Cattaneo M. Are the bleeding time and PFA-100 useful in the initial screening of patients with mucocutaneous bleedings of hereditary nature?.  J Thromb Haemost. 2004;  2 890-891
• 100 Yee D L, Sun C W, Bergeron A L, Dong J F, Bray P F. Aggregometry detects platelet hyperreactivity in healthy individuals.  Blood. 2005;  106 2723-2729
• 101 Holmsen H, Dangelmaier C A. Measurement of secretion of serotonin.  Methods Enzymol. 1989;  169 205-210
• 102 McGlasson D, Fritsma G. Whole blood platelet aggregometry and platelet function testing.  Semin Thromb Hemost. 2009;  35 168-180
• 103 Wall J E, Buijs-Wilts M, Arnold J T et al.. A flow cytometric assay using mepacrine for study of uptake and release of platelet dense granule contents.  Br J Haematol. 1995;  89 380-385
• 104 White J G. Electron opaque structures in human platelets: which are or are not dense bodies?.  Platelets. 2008;  19 455-466
• 105 Kumar A M, Kumar M, Deepika K, Fernandez J B, Eisdorfer C. A modified HPLC technique for simultaneous measurement of 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in cerebrospinal fluid, platelet and plasma.  Life Sci. 1990;  47 1751-1759
• 106 Maurer-Spurej E, Pittendreigh C, Wu J K. Diagnosing platelet delta-storage pool disease in children by flow cytometry.  Am J Clin Pathol. 2007;  127 626-632
• 107 Maurer-Spurej E, Dyker K, Gahl W A, Devine D V. A novel immunocytochemical assay for the detection of serotonin in platelets.  Br J Haematol. 2002;  116 604-611
• 108 Koch C A, Lasho T L, Tefferi A. Platelet-rich plasma serotonin levels in chronic myeloproliferative disorders: evaluation of diagnostic use and comparison with the neutrophil PRV-1 assay.  Br J Haematol. 2004;  127 34-39
• 109 Holmsen H, Dangelmaier C A. Measurement of secretion of adenine nucleotides.  Methods Enzymol. 1989;  169 195-205
• 110 Edenbrandt C M, Murphy S. Adenine and guanine nucleotide metabolism during platelet storage at 22 degrees C.  Blood. 1990;  76 1884-1892
• 111 White M M, Foust J T, Mauer A M, Robertson J T, Jennings L K. Assessment of lumiaggregometry for research and clinical laboratories.  Thromb Haemost. 1992;  67 572-577
• 112 Axelson D A, Perel J M, Birmaher B et al.. Platelet serotonin reuptake inhibition and response to SSRIs in depressed adolescents.  Am J Psychiatry. 2005;  162 802-804
• 113 Nurden A T, Nurden P, Bermejo E, Combrié R, McVicar D W, Washington A V. Phenotypic heterogeneity in the gray platelet syndrome extends to the expression of TREM family member, TLT-1.  Thromb Haemost. 2008;  100 45-51
• 114 Weiss H J, Witte L D, Kaplan K L et al.. Heterogeneity in storage pool deficiency: studies on granule-bound substances in 18 patients including variants deficient in alpha-granules, platelet factor 4, beta-thromboglobulin, and platelet-derived growth factor.  Blood. 1979;  54 1296-1319
• 115 Lages B, Weiss H J. Heterogeneous defects of platelet secretion and responses to weak agonists in patients with bleeding disorders.  Br J Haematol. 1988;  68 53-62
• 116 Rao A K. Acquired qualitative platelet defects. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th ed. Philadelphia, PA; Lippincott Williams & Wilkins 2006: 1045-1060
• 117 Sadler J E. Von Willebrand disease type 1: a diagnosis in search of a disease.  Blood. 2003;  101 2089-2093
• 118 Sadler J E. Slippery criteria for von Willebrand disease type 1.  J Thromb Haemost. 2004;  2 1720-1723
• 119 Gerhardt A, Scharf R E, Beckmann M W et al.. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium.  N Engl J Med. 2000;  342 374-380
• 120 Anderson Jr F A, Spencer F A. Risk factors for venous thromboembolism.  Circulation. 2003;  107(23, Suppl 1) I9-I16
• 121 Jennings L K, Ashmun R A, Wang W C, Dockter M E. Analysis of human platelet glycoproteins IIb-IIIa and Glanzmann's thrombasthenia in whole blood by flow cytometry.  Blood. 1986;  68 173-179
• 122 Cohn R J, Sherman G G, Glencross D K. Flow cytometric analysis of platelet surface glycoproteins in the diagnosis of Bernard-Soulier syndrome.  Pediatr Hematol Oncol. 1997;  14 43-50
• 123 Enjeti A K, Lincz L F, Seldon M. Detection and measurement of microparticles: an evolving research tool for vascular biology.  Semin Thromb Hemost. 2007;  33 771-779
• 124 van Engeland M, Nieland L J, Ramaekers F C, Schutte B, Reutelingsperger C P. Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure.  Cytometry. 1998;  31 1-9
• 125 Bigalke B, Langer H, Geisler T, Lindemann S, Gawaz M. Platelet glycoprotein VI: a novel marker for acute coronary syndrome.  Semin Thromb Hemost. 2007;  33 179-184
• 126 Michelson A D, Furman M I. Laboratory markers of platelet activation and their clinical significance.  Curr Opin Hematol. 1999;  6 342-348